Trial Profile
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Ages 4 to 17 Years (RAMSES)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Jul 2022
Price :
$35
*
At a glance
- Drugs AR 101 (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions; Registrational
- Acronyms RAMSES
- Sponsors Aimmune Therapeutics
- 30 Jun 2022 Results presented in the Aimmune Therapeutics Media Release.
- 30 Jun 2022 According to an Aimmune Therapeutics media release, results from an analysis to be presented on health-related quality of life (HRQoL) among patients from the Phase 3 PALISADE, ARC004 (PALISADE follow-on), ARTEMIS, RAMSES and ARC011 (RAMSES follow-on) trials will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress.
- 16 Feb 2022 Results published in an Aimmune Therapeutics Media Release.